Press 
Releases 

ARTICLES

4 March 2026
Mursla Bio accelerates US commercial deployment of EvoLiver through ABHI programme
Programme builds on existing US footprint and strengthens EvoLiver’s path to US clinical adoption
13 November 2025
Mursla Bio collaborates with a leading global pharma company to advance biomarker-guided precision medicine in MASH
AI Precision Medicine Platform to inform drug development and patient stratification in metabolic liver disease
17 June 2025
Mursla Bio introduces AI Precision Medicine Platform built on organ-specific EV isolation from blood
Organ-specific, AI-ready multi-omics platform validated for liver disease diagnostics and monitoring
23 April 2025
Mursla Bio receives FDA Breakthrough Device Designation for EvoLiver™ test
Reflects the potential of EvoLiver™ test to improve early liver cancer detection among high-risk patients
18 November 2024
Mursla Bio’s EvoLiver™ surpasses current standards in liver cancer surveillance, data presented at AASLD Liver Meeting 2024

EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with …